Voltar
Artigo Revisado por pares
BIBTEX RIS

Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2)

2017; Springer Science+Business Media; Volume: 164; Issue: 2 Linguagem: Inglês

10.1007/s10549-017-4261-1

ISSN

1573-7217

Autores

Cornelia von Hagens, I. Walter‐Sack, Maren Goeckenjan, Julia Osburg, B. Storch–Hagenlocher, Serkan Sertel, Michael Elsässer, Bjoern Andrew Remppis, Lutz Edler, J Munzinger, Thomas Efferth, Andreas Schneeweiß, T. Strowitzki,

Tópico(s)

PARP inhibition in cancer therapy

Referência(s)